0001636282-26-000053.txt : 20260508 0001636282-26-000053.hdr.sgml : 20260508 20260508213149 ACCESSION NUMBER: 0001636282-26-000053 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260508 FILED AS OF DATE: 20260508 DATE AS OF CHANGE: 20260508 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HENDERSON MICHAEL THOMAS CENTRAL INDEX KEY: 0001779990 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37722 FILM NUMBER: 26960579 MAIL ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Spyre Therapeutics, Inc. CENTRAL INDEX KEY: 0001636282 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 464312787 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 221 CRESCENT STREET STREET 2: BUILDING 23, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 6176515940 MAIL ADDRESS: STREET 1: 221 CRESCENT STREET STREET 2: BUILDING 23, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: Aeglea BioTherapeutics, Inc. DATE OF NAME CHANGE: 20150311 4 1 wk-form4_1778290306.xml FORM 4 X0609 4 2026-05-08 0 0001636282 Spyre Therapeutics, Inc. SYRE 0001779990 HENDERSON MICHAEL THOMAS false 221 CRESCENT STREET, BUILDING 23, SUITE 105 WALTHAM MA 02453 1 0 0 0 1 Common Stock 2026-05-08 4 S 0 2404 72.57 D 166202 D Common Stock 2026-05-08 4 S 0 33513 73.72 D 132689 D Common Stock 2026-05-08 4 S 0 24814 74.76 D 107875 D Common Stock 2026-05-08 4 S 0 19269 75.35 D 88606 D This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $72.03 to $73.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.15 to $74.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.15 to $75.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $75.15 to $75.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. /s/ Heidy King-Jones, as Attorney-in-Fact 2026-05-08